ERAS (Erasca) Other Financing: $-14.09 Mil (TTM As of Mar. 2026)


ERAS Erasca Inc ERAS
22 GF Score
Price $15.94
! 3 Warning Signs
View Full Analysis

What is Erasca Other Financing?

Erasca ERAS +7.09% 22 Other Financing is $-14.09 Mil as of Mar. 2026. GuruFocus rates ERAS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Erasca's Other Financing for the three months ended in Mar. 2026 was $-14.09 Mil.

Erasca's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $-14.09 Mil.

Erasca Other Financing Historical Data

* Premium members only.

The historical data trend for Erasca's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Erasca Other Financing Chart

Erasca Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 3.01 2.82 0.00 1.64 0.00

Erasca Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -14.09
ERAS
22GF Score
Erasca Inc ERAS
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Erasca Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-14.09 Mil mean?
Erasca (ERAS) has a Other Financing of $-14.09 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Erasca and its competitors.
Is Erasca's Other Financing too high?
Erasca's current Other Financing is $-14.09 Mil. Overall, Erasca has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Erasca's Other Financing compare to NAMS and CPRX?
Erasca's Other Financing of $-14.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Erasca and its competitors. Erasca's current Other Financing is $-14.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Erasca stock overvalued right now?
Erasca (ERAS) has a current Other Financing of $-14.09 Mil. The current Other Financing is $-14.09 Mil. Erasca's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Erasca (ERAS), the current Other Financing is $-14.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Erasca Business Description

Address 3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
22GF Score

Get the complete analysis for ERAS

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.94
Price